Veterinary Molecular Diagnostics Market Size, Share and Analysis by Animal (Livestock, Companion), By Product (Instruments & Software, Kit & Reagents, Services), By Disease Indications (Infectious diseases, Respiratory diseases, Metabolic diseases), By End User (Hospitals, Clinics, Others) and Regional Forecast, 2026-2034

The global veterinary molecular diagnostics market size was valued at USD 1.38 billion in 2025. The market is projected to grow from USD 1.52 billion in 2026 to USD 3.42 billion by 2034, exhibiting a CAGR of 10.63% during the forecast period.

The molecular diagnostic is a technique utilized for the identification of the disease or its stage analyses by the RNA or DNA or other proteins in human and animals. Veterinary molecular diagnostics are done on samples taken from animals. Developments in the animal healthcare sector and concern for animal health have increased the demand for fast molecular diagnostic techniques for animals.

Few molecular diagnostic techniques involve polymerase chain response (PCR), fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), nanotechnology, biochips, proteomic innovations, and electrochemical location of DNA. High sensitivity and specificity of the test and new product launch have surged the veterinary molecular diagnostics market.

To gain extensive insights into the market, Download for Customization

The rising prevalence of various animal diseases is expected to drive the growth of the global veterinary molecular diagnostics market over the forecast period. Additionally, factors such as growing importance for animal health, rise in a number of veterinary diagnostic centers, adoption of advanced diagnostic techniques, and widened focus on food safety are anticipated to fuel the global veterinary molecular diagnostics market.

However, high costs associated with sophisticated molecular diagnostics instruments and assays and lack of skilled technicians are some of the factors restraining the growth of the global veterinary molecular diagnostics market.

Key Players Covered

Some of the major companies that are present in the global veterinary molecular diagnostics market are Biomedica Medizinprodukte GmbH & Co KG, IDEXX Laboratories, Inc., Thermo Fisher Scientific, Inc., VCA, Inc., Novacyt Group, QIAGEN N.V., HealthGene Corporation, Bioneer, and others.

SEGMENTATION

Among the segmentation, instruments and software segment is anticipated to hold a considerable share of the global veterinary molecular diagnostics market due to high pricing of the instruments, new product launch, and rapid adoption of diagnostic software.

Key Insights

• Prevalence of animal disease for key countries
• Overview of veterinary molecular diagnostic services
• The regulatory scenario for key countries
• New product launch
• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America is projected to dominate the global veterinary molecular diagnostics market over the forecast period owing to the high incidence of animal diseases, the increase in government & private funding for animal health, and a large volume of tests performed. The veterinary molecular diagnostics market in Europe is projected to expand due to high usage of superior-quality diagnostics techniques, active government support, and an increase in a number of veterinary diagnostic centers. Asia Pacific is expected to register significant growth over the forecast period owing to the increase in the number of diagnostic laboratories, government and private funding for veterinary health care activities, and rising awareness about veterinary molecular diagnostics in the region.

Key Industry Developments

• In March 2018, BioChek announced the launch of Salmonella Enteritidis-Typhimurium-Heidelberg DNA Test Kit and Infectious Bronchitis Virus RNA Test Kit for the detection in avian samples.
• In February 2018, BioChek announced the introduction of Avian Influenza H5-H7-H9 Multiplex, a PCR testing kit for the diagnosis of influenza in poultry.
• In September 2017, Neogen announced the acquisition of The University of Queensland Animal Genetics Laboratory (AGL), which made the company the fourth animal genomics laboratory.